Lillie James Woodruff 4
4 · MapLight Therapeutics, Inc. · Filed Jan 29, 2026
Research Summary
AI-generated summary of this filing
MapLight Therapeutics CSO Lillie James Woodruff Withholds 45,055 Shares
What Happened
Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics (MPLT), had 45,055 shares withheld to satisfy tax withholding obligations upon settlement of restricted stock units. The withholding was executed on January 27, 2026 at a price of $17.98 per share, for a total value of approximately $810,089. This is a tax-withholding disposition (routine), not a purchase or open-market sale.
Key Details
- Transaction date and price: 2026-01-27, 45,055 shares withheld at $17.98/share (total ~$810,089).
- Transaction code: F — shares withheld to satisfy tax withholding on RSU settlement.
- Shares owned after transaction: Not disclosed in the excerpt provided.
- Filing date: 2026-01-29 (filed within the normal 2-business-day reporting window).
- Footnote: The shares were retained by the issuer to cover taxes and remain subject to the issuer's 180-day IPO lock-up tied to the Oct 26, 2025 prospectus (lock-up ending around Apr 24, 2026), per the filing.
Context
This was a cashless tax-withholding on RSU settlement (common and administrative). Such withholdings are routine and do not necessarily indicate the insider’s sentiment about the stock. The retained shares remain subject to the IPO lock-up restrictions noted above.
Insider Transaction Report
- Tax Payment
Voting Common Stock
[F1]2026-01-27$17.98/sh−45,055$810,089→ 291,132 total
Footnotes (1)
- [F1]Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.